These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 20725807)

  • 1. Significance of vascular endothelial growth factor, interleukin-18 and nitric oxide in patients with breast cancer: correlation with carbohydrate antigen 15.3.
    Metwally FM; El-mezayen HA; Ahmed HH
    Med Oncol; 2011 Dec; 28 Suppl 1():S15-21. PubMed ID: 20725807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of serum IL-18 and nitric oxide activity in breast cancer patients at operable stage.
    Günel N; Coskun U; Sancak B; Hasdemir O; Sare M; Bayram O; Celenkoglu G; Ozkan S
    Am J Clin Oncol; 2003 Aug; 26(4):416-21. PubMed ID: 12902898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
    Findeisen R; Albrecht S; Richter B; Deutschmann K; Zimmermann T; Distler W
    Luminescence; 2000; 15(5):283-9. PubMed ID: 11038485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation of serum vascular endothelial growth factor as an angiogenesis biomarker with nitric oxide & urokinase-type plasminogen activator in breast cancer patients.
    Konukoglu D; Turhan MS; Celik V; Turna H
    Indian J Med Res; 2007 Jun; 125(6):747-51. PubMed ID: 17704550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical importance of serum interleukin-18 and nitric oxide activities in breast carcinoma patients.
    Günel N; Coşkun U; Sancak B; Günel U; Hasdemir O; Bozkurt S
    Cancer; 2002 Aug; 95(3):663-7. PubMed ID: 12209760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical value of serum hepatocyte growth factor, B-cell lymphoma-2 and nitric oxide in primary breast cancer patients.
    Ahmed HH; Metwally FM; Mahdy ES; Shosha WG; Ramadan SS
    Eur Rev Med Pharmacol Sci; 2012 Jul; 16(7):958-65. PubMed ID: 22953646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of angiogenic factors in early breast cancer remain close to normal.
    Duranyildiz D; Camlica H; Soydinc HO; Derin D; Yasasever V
    Breast; 2009 Feb; 18(1):26-9. PubMed ID: 18996696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Taurine: a novel tumor marker for enhanced detection of breast cancer among female patients.
    El Agouza IM; Eissa SS; El Houseini MM; El-Nashar DE; Abd El Hameed OM
    Angiogenesis; 2011 Sep; 14(3):321-30. PubMed ID: 21553281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Basic fibroblast growth factor and vascular endothelial growth factor serum levels in breast cancer patients and healthy women: useful as diagnostic tools?
    Granato AM; Nanni O; Falcini F; Folli S; Mosconi G; De Paola F; Medri L; Amadori D; Volpi A
    Breast Cancer Res; 2004; 6(1):R38-45. PubMed ID: 14680499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status.
    Heer K; Kumar H; Read JR; Fox JN; Monson JR; Kerin MJ
    Clin Cancer Res; 2001 Nov; 7(11):3491-4. PubMed ID: 11705867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Level of CA 15-3 antigen--a prognostic factor in patients with breast cancer?].
    Wojtacki J; Dziewulska-Bokiniec A; Kowalski DM; Zółtowska A; Ciesielski D; Suszko M
    Przegl Lek; 1996; 53(11):788-92. PubMed ID: 9173440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of serum VEGF and its soluble receptor sVEGFR1 with serum cell-free DNA in patients with breast tumor.
    El Tarhouny S; Seefeld M; Fan AX; Hahn S; Holzgreve W; Zhong XY
    Cytokine; 2008 Oct; 44(1):65-9. PubMed ID: 18691902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
    Ławicki S; Szmitkowski M; Wojtukiewicz M
    Clin Chim Acta; 2006 Sep; 371(1-2):112-6. PubMed ID: 16631152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer.
    Iovino F; Ferraraccio F; Orditura M; Antoniol G; Morgillo F; Cascone T; Diadema MR; Aurilio G; Santabarbara G; Ruggiero R; Belli C; Irlandese E; Fasano M; Ciardiello F; Procaccini E; Lo Schiavo F; Catalano G; De Vita F
    Cancer Invest; 2008; 26(3):250-5. PubMed ID: 18317965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer].
    Tang JH; Zhao JH; Gong JP; Qin JW; Pan LQ; Xu ZY
    Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):210-4. PubMed ID: 17649639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative plasma vascular endothelial growth factor but not nitrite is a useful complementary tumor marker in patients with colorectal cancer.
    Tsai WS; Changchien CR; Yeh CY; Chen JS; Tang R; Chiang JM; Hsieh PS; Fan CW; Wang JY
    Dis Colon Rectum; 2006 Jun; 49(6):883-94. PubMed ID: 16741643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VEGF, IL-18 and NO production by neutrophils and their serum levels in patients with oral cavity cancer.
    Jablonska E; Puzewska W; Grabowska Z; Jablonski J; Talarek L
    Cytokine; 2005 May; 30(3):93-9. PubMed ID: 15826815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The plasma levels and diagnostic utility of selected hematopoietic growth factors (HGFs) in breast cancer patients].
    Ławicki S; Czygier M; Wojtukiewicz M; Szmitkowski M
    Przegl Lek; 2010; 67(12):1314-8. PubMed ID: 21591359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer.
    Eskelinen M; Kataja V; Hämäläinen E; Kosma VM; Penttilä I; Alhava E
    Anticancer Res; 1997; 17(2B):1231-4. PubMed ID: 9137478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VEGF, M-CSF and CA 15-3 as a new tumor marker panel in breast malignancies: a multivariate analysis with ROC curve.
    Ławicki S; Będkowska GE; Szmitkowski M
    Growth Factors; 2013 Jun; 31(3):98-105. PubMed ID: 23688065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.